Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Review
. 2014 Jun;8(4):830-9.
doi: 10.1016/j.molonc.2014.03.004. Epub 2014 Mar 18.

Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe

Hendrikus J Dubbink  1 , Zandra C Deans  2 , Bastiaan B J Tops  3 , Folkert J van Kemenade  1 , S Koljenović  1 , Han J M van Krieken  3 , Willeke A M Blokx  3 , Winand N M Dinjens  1 , Patricia J T A Groenen  4
Affiliations
Review

"VSports注册入口" Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe

Hendrikus J Dubbink et al. Mol Oncol. 2014 Jun.

Abstract

Tumor evaluation in pathology is more and more based on a combination of traditional histopathology and molecular analysis. Due to the rapid development of new cancer treatments that specifically target aberrant proteins present in tumor cells, treatment decisions are increasingly based on the molecular features of the tumor. Not only the number of patients eligible for targeted precision medicine, but also the number of molecular targets per patient and tumor type is rising. Diagnostic molecular pathology, the discipline that determines the molecular aberrations present in tumors for diagnostic, prognostic or predictive purposes, is faced with true challenges. The laboratories have to meet the need of comprehensive molecular testing using only limited amount of tumor tissue, mostly fixed in formalin and embedded in paraffin (FFPE), in short turnaround time VSports手机版. Choices must be made for analytical methods that provide accurate, reliable and cost-effective results. Validation of the test procedures and results is essential. In addition, participation and good performance in internal (IQA) and external quality assurance (EQA) schemes is mandatory. In this review, we critically evaluate the validation procedure for comprehensive molecular tests as well as the organization of quality assurance and assessment of competence of diagnostic molecular pathology laboratories within Europe. .

Keywords: Molecular pathology; Next generation sequencing; Proficiency testing; Quality assessment; Quality assurance; Tumor testing V体育安卓版. .

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed model for the interaction between the EQA providers, the National Body and ISO 15189‐accredited laboratories. Each European country has an independent National body with a mandate to enforce laboratories to become ISO 15189 accredited and to participate in EQA schemes. In case of poor performance, there will be an encouraging interaction between the EQA provider and the laboratory. In case of persistent poor performance, the EQA provider will communicate this to the National Body who will undertake adequate steps.
Figure 2
Figure 2
Proposed framework for the organization of EQA schemes in Europe. EQA programmes are organized under supervision of the European Society for Pathology and/or a European Quality Assurance Council (van Krieken et al., 2008). A European organization for the coordination of EQA schemes determines in collaboration with representatives from the different participating countries and the EQA providers which schemes should be provided. One or several EQA provider(s) coordinate(s) collecting representative tissues or in silico data and distribution of a scheme as well as evaluation and feedback of the performance to all participating laboratories and in case of persistent poor performance to a National Body as depicted in Figure 1.
See this image and copyright information in PMC

References

    1. Beadling, C. , Heinrich, M.C. , Warrick, A. , 2011. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J. Mol. Diagn.. 13, 504–513. - PMC - PubMed
    1. Bellon, E. , Ligtenberg, M.J. , Tejpar, S. , 2011. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist. 16, 467–478. - PMC - PubMed
    1. Blokx, W.A. , Lesterhuis, W.J. , Andriessen, M.P. , 2007. CDKN2A (INK4A-ARF) mutation analysis to distinguish cutaneous melanoma metastasis from a second primary melanoma. Am. J. Surg. Pathol.. 31, 637–641. - PubMed
    1. Bovee, J.V. , Hogendoorn, P.C. , 2010. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch.. 456, 193–199. - PMC - PubMed
    1. Cancer Genome Atlas Research, 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455, 1061–1068. - PMC - PubMed